- Report
- November 2024
- 257 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- September 2021
- 40 Pages
China
From €2366EUR$2,600USD£2,029GBP
- Report
- November 2023
- 224 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- September 2023
- 112 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- November 2023
- 353 Pages
Global
From €8646EUR$9,500USD£7,412GBP
- Report
- April 2023
- 180 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- July 2023
- 87 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Book
- July 2023
- 320 Pages
Tamoxifen is a drug used to treat breast cancer. It is a selective estrogen receptor modulator (SERM) that works by blocking the effects of estrogen in the body. Tamoxifen is used to treat both early and advanced stages of breast cancer, and is often used in combination with other drugs. It is also used to reduce the risk of breast cancer in women at high risk of developing the disease. Tamoxifen is available in both oral and injectable forms, and is typically taken for five to ten years.
Tamoxifen is one of the most widely used drugs for the treatment of breast cancer, and is often prescribed in combination with other drugs. It is also used to reduce the risk of recurrence in women who have already been treated for breast cancer.
The Tamoxifen market is highly competitive, with many companies offering generic versions of the drug. Companies such as Pfizer, AstraZeneca, Novartis, and Teva Pharmaceuticals are some of the major players in the market. Other companies such as Mylan, Sun Pharmaceuticals, and Dr. Reddy's Laboratories also offer generic versions of Tamoxifen. Show Less Read more